Douglas Fambrough, Dicerna CEO (Boehringer Ingelheim via YouTube)
Roche-backed Dicerna pushes into the pack racing toward the blockbuster hep B goal line, armed with PhI data
Dicerna has lined up a set of proof-of-concept data from a small cohort of hepatitis B patients in a match-up against some heavyweight rivals which …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
